- Home
- BCDA vs DGLY Comparison
BCDA vs DGLY Comparison
Compare BCDA & DGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- DGLY
- Stock Information
- Founded
- BCDA N/A
- DGLY 2004
- Country
- BCDA United States
- DGLY United States
- Employees
- BCDA N/A
- DGLY N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- DGLY Radio And Television Broadcasting And Communications Equipment
- Sector
- BCDA Health Care
- DGLY Technology
- Exchange
- BCDA Nasdaq
- DGLY Nasdaq
- Market Cap
- BCDA 7.9M
- DGLY 3.8M
- IPO Year
- BCDA N/A
- DGLY N/A
- Fundamental
- Price
- BCDA $2.68
- DGLY $1.03
- Analyst Decision
- BCDA Strong Buy
- DGLY
- Analyst Count
- BCDA 1
- DGLY 0
- Target Price
- BCDA $25.00
- DGLY N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- DGLY 58.4K
- Earning Date
- BCDA 11-06-2024
- DGLY 11-12-2024
- Dividend Yield
- BCDA N/A
- DGLY N/A
- EPS Growth
- BCDA N/A
- DGLY N/A
- EPS
- BCDA N/A
- DGLY N/A
- Revenue
- BCDA $428,000.00
- DGLY $23,417,110.00
- Revenue This Year
- BCDA $6.92
- DGLY $22.14
- Revenue Next Year
- BCDA N/A
- DGLY N/A
- P/E Ratio
- BCDA N/A
- DGLY N/A
- Revenue Growth
- BCDA 0.71
- DGLY N/A
- 52 Week Low
- BCDA $1.96
- DGLY $0.84
- 52 Week High
- BCDA $23.25
- DGLY $3.29
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- DGLY 46.14
- Support Level
- BCDA $2.39
- DGLY $0.95
- Resistance Level
- BCDA $2.90
- DGLY $1.07
- Average True Range (ATR)
- BCDA 0.18
- DGLY 0.06
- MACD
- BCDA -0.00
- DGLY 0.01
- Stochastic Oscillator
- BCDA 53.70
- DGLY 36.36
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About DGLY Digital Ally Inc.
Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.